PharmaZen first-half profit up 23%
Profit was $290,000 in the six months ended June 30.
PharmaZen, the Christchurch-based animal and human nutrition manufacturer, said first-half profit rose 23 percent as an increase in sales was offset by the impact of a strong kiwi dollar and higher depreciation charges.
The company whose shares trade on the Unlisted platform, said profit was $290,000 in the six months ended June 30, from $230,000 a year earlier. Turnover rose to $3.71 million from $3.63 million.
Shares of PharmaZen, which first listed in July 2004, last traded at 7 cents, valuing the company at $11.2 million. That's up from 4.5 cents a year ago, although the stock trades infrequently. The less onerous disclosure rules for Unlisted compared to the NZX means the first-half results were covered in a one-page media release. It is predominantly owned by investors in Dunedin and Otago.
PharmaZen's trading arm is Waitaki Biosciences, which has been making and globally marketing natural nutritional products for 20 years, according to its website. Its products include calcium supplements, a mussel extract marketed for joint health, and extracts from blackcurrants and kiwifruit.
"The dollar aside, we continue to make progress in many areas of the business with the main highlight being the completion of all regulatory hurdles for the solvent extraction plant, with the first pilot production scheduled for September," said chief executive Craig McIntosh. ""We have received strong interest across the intended range of products and expect to be selling commercial volumes in the fourth quarter."
(BusinessDesk)
Click the hamburger symbol top right of our homepage to access the Rich List 2016 and other sections.
Jonathan Underhill
Mon, 05 Sep 2016
Mon, 05 Sep 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
PharmaZen first-half profit up 23%
61383